Biomarker quantification and cytokine measurement
Measure a biomarker or cytokine in patient serum or plasma and confirm real binding signal.
Concentration and binding behaviour read from the same trace.
active concentration
Anti-drug antibody assays and binding kinetics, directly in serum, plasma, and CSF
Crude samples contain proteins and lipids that cause non-specific binding. A special surface minimizes these interactions, so an anti-drug antibody assay, pharmacokinetic assay or biomarker measurement reads affinity, kinetics and active concentration directly, with minimal prep using only a 0.22 µm filter.
How label-free analysis helps in complex matrices
Biomarker quantification measured directly in serum, plasma, CSF, or urine, with no tag on either partner.
Pharmacokinetic assay and drug concentration
Measure drug-target binding directly in crude samples, from preclinical PK/PD and animal studies through to human samples.
automated runs
regenerable chip
Anti-drug antibody assay and immunogenicity assessment
Characterize an ADA response as kinetics, not only as titer.
Anti-drug antibody testing and a neutralizing antibody assay both run in the matrix the sample arrived in.
ADA kinetics
Studies with limited sample material
Run a target with its controls and related markers from one small sample, in animal work, paediatric studies, or microsampling.
16 sensors on a single chip carry the panel, spotter required.
16 sensors
Diagnostic assay development
Screen capture reagents and surface chemistries against real matrix early.
Find out what holds up in matrix while the assay design can still change.
capture screening
assay development
Don't see your application?
Discuss your assay with one of our application specialists.
Talk to a specialist
Benefits of the inQuiQ in complex biological matrices
01 / 04
One injection, four channels, sixteen sensors
Four independently addressable flow channels, each carrying four sensors, with the sample flowing through the channels in series.
30 µL minimumsequential flow paths
Serum and plasma read as clean traces
An antifouling hydrogel layer limits adsorption of matrix proteins and lipids, and a reference channel carries what remains, so specific binding is separated from background.
bar length shows non-specific signal, not analyte response
antifouling hydrogelreferencing
what sticks, and what does not
The whole binding event, not one endpoint number
a sandwich ELISA or an MSD read report how much analyte is there at a fixed timepoint. The inQuiQ records binding in real-time, so rate, stability, and active concentration all come from the same trace.
kon, koff, KDactive concentration
four injections, or four endpoint numbers
Filter, inject, and the run is under way
Unpurified samples go straight in once they have passed a 0.22 µm filter, undiluted or diluted.
- No extraction or cleanup step between the sample and the sensor
0.22 µm filter
straight from sample to sensor
From sample to sensorgram
Every measurement follows the same steps, whatever the matrix. A capture reagent is immobilized on the sensor, the filtered sample flows past, and the instrument records the response in real time. An endpoint assay gives you one number. The inQuiQ gives you the full curve.
Immobilization
The capture reagent is attached to the sensor surface first.
Amine coupling or tag capture holds the target on an antifouling hydrogel layer that limits serum and plasma sticking. A reference channel without capture reagent runs alongside it, so matrix background is subtracted from every injection.
- amine coupling
- capture
- antifouling hydrogel
Deactivation
Unused activated sites are capped before the first sample arrives.
Without deactivation, the surface reacts with whatever passes over. In serum or plasma, matrix proteins and lipids then enter the trace instead of the pair being measured. The response settles at the immobilized amount.
- deactivation
- blocking
- non-specific binding
Association
The filtered sample flows across the surface and the response climbs.
Serum, plasma, CSF, or urine goes in undiluted or diluted after a 0.22 µm filter. Flow rate sets contact time, and injections up to 2 mL give dilute analytes longer at the surface. The rising phase gives the on-rate, ka.
- 0.22 µm filter
- referencing
- ka
Dissociation
Buffer replaces the sample and the response falls as the complex comes apart.
The dissociation phase gives the off-rate. A concentration series yields ka, kd, and KD in the sample matrix. For an ADA response or drug-target pair, that gives a kinetic profile alongside titer, with active concentration rather than total mass.
- residence time
- kd
- KD
- active concentration
Regeneration
A regeneration buffer strips what remains and returns the sensor to baseline.
The immobilized capture reagent stays in place, so every sample meets the same surface. Inject, read, regenerate, repeat, unattended. Every sensor reads each injection, so one small sample can cover a marker panel or a target with mismatch and off-target controls.
- regeneration
- automated cycling
- off-target controls
Response (RU)
Time
What the inQuiQ does for work in complex matrices
One modular benchtop label-free biosensor for biomarker quantification, immunogenicity assessment, and more.
Clean signal from dirty samples
An antifouling hydrogel layer limits non-specific binding, so serum, plasma and CSF sample analysis all run without extensive cleanup.
antifouling hydrogel
serum, plasma, CSF
Real-time ADA and PK-style data
Full on and off rates in matrix, so immunogenicity and drug binding are characterized as kinetic profiles rather than single endpoint values.
ka, kd, KD
Active concentration, not total mass
Binding activity is measured directly, which separates functional analyte from material that is present but not working.
active concentration
A target and its controls from one small sample
30 µL is enough for a measurement, and with a spotter 16 sensors carry a biomarker panel, or a target plus its specificity controls, on one chip.
16 sensors (spotter required)
Stable baseline across long sample series
Drift stays typically below 0.3 RU per minute, so a full plate of study samples reads against the same reference.
< 0.3 RU/min drift
Consistent results across a study series
Run toxicology, animal efficacy, and human samples on the same regenerable chip and consistent conditions, keeping results comparable across the programme.
2×384 wells
regenerable chip
Explore the inQuiQ768
Application notes, publications, and data
From small molecule kinetics to antibody affinity, explore real binding data generated on inQuiQ. Each application note pairs a sensorgram with the affinity and kinetic values behind it.
Start A conversation
Talk to an application scientist
Bring us a matrix that has been giving you trouble. We will look at the assay design with you.
Ready to see the inQuiQ in action?
Talk to an application scientist
Thirty minutes to discuss your assay design, before anyone mentions an instrument.
Download the inQuiQ brochure
Sensitivity, channel layout, footprint, and consumable formats in a couple of pages.
Delta Life Science
request@deltalifescience.nl
Send us an email, and we will get back to you as soon as possible.
request@deltalifescience.nl
Send us an email, and we will get back to you as soon as possible.
Questions researchers ask
Immobilise a capture reagent on an antifouling sensor surface, then inject filtered serum and follow binding in real time. The antifouling hydrogel limits non-specific adsorption from matrix proteins and lipids. Reference channels correct for bulk effects, so the remaining signal reflects specific binding, giving KD, kon, and koff directly in serum. The same approach supports CSF sample analysis.
Three things do most of the work: surface chemistry that resists adsorption, referencing against a control channel to subtract bulk and background effects, and filtering the sample through a 0.22 µm filter. The antifouling hydrogel layer on the inQuiQ chips handles the first, and the 4-channel chip supports the second, , making it suitable for diagnostic assay development in real matrices.
MSD is an endpoint electrochemiluminescence method: it reports how much ADA is present at one timepoint, with a tag on the detection reagent. Label-free anti drug antibody testing and ADA immunogenicity testing adds real-time association and dissociation with no tag, so the response can be described by its kinetics and stability, not only its level. Free drug still competes with antibody for the target, so the same sample handling a drug tolerance ADA assay needs applies here too.
No. Unpurified samples run directly once filtered through a 0.22 µm filter. Minimum sample volume is 30 µL, and up to 2 mL can be used when a low-concentration analyte needs longer contact time with the sensor surface.
The standard 4-channel photonic chip supports up to 4-plex with no extra hardware. With a microarray spotter all 16 sensors can be immobilized individually, so label-free biomarker quantification or a target plus mismatch and off-target controls can be read from a single small sample injection.
Yes. The inQuiQ supports diagnostic assay development by testing capture reagents, surface chemistries, and assay conditions directly in relevant sample matrices. Label-free measurements provide binding affinity, kinetics, and active concentration while reference channels help separate specific binding from matrix effects.